UBS Reiterates Buy Rating on Altimmune (ALT)

UBS analyst Eliana Merle reiterated a Buy rating and $26.00 price target on Altimmune (NASDAQ: ALT).

The analyst commented, "In an ITT analysis pemvidutide meets MASH resolution endpoint but misses fibrosis improvement, which had been a key endpoint of investor focus… Though we continue to think pem is active in MASH & would be likely to show greater efficacy over time (fibrosis benefit at 24 weeks from pem is somewhat similar to what semaglutide showed at 72 weeks), we think for investors cash runway will become a key question here given this data. We do see rationale for pem across MASH and obesity as well as alcohol use disorders (which ALT says it can fund on its own) & see long term value potential from pem still, though data on fibrosis were less compelling than we had hoped for."

For an analyst ratings summary and ratings history on Altimmune click here. For more ratings news on Altimmune click here.

Shares of Altimmune closed at $3.61 yesterday.

You May Also Be Interested In

• DT Midstream (DTM) Reiterated at Buy by UBS After Investor Dinner
• AmerX Starts Serve Robotics (SERV) at Buy
• AmerX Starts WidePoint Corp (WYY) at Buy